Quietly more freedom, Dexcom Stelo CGM moves beyond insulin users

Reviewed: ad hoc news Accessory & Components desk. Edited and checked on 2026-06-18, 01:23. Details in the imprint.

With Dexcom Stelo on the upper arm, the diabetes tech suddenly looks less like a medical device and more like a discreet sticker. No finger-pricks, just a vibration on the phone when glucose drifts too high, especially for people who never saw themselves as "typical" CGM users.

What Dexcom Stelo is built for

Dexcom positions Stelo as a continuous glucose monitor specifically for adults with type 2 diabetes and those with prediabetes who are not on insulin therapy, separating it clearly from the G7 system aimed at insulin users.

Instead of dosing decisions, Stelo focuses on trends: how breakfast, a walk after dinner, or a stressful meeting move the curve up and down across the day.

The sensor on the arm

The Stelo sensor is a small round patch that sits on the back of the upper arm for around 15 days, according to Dexcom's launch material for the over-the-counter device.

Once applied with an automatic inserter, there is no visible needle, just a flat white puck under a T-shirt sleeve that quietly streams glucose values to a smartphone app.

From adults to children

Initially, the FDA cleared Dexcom Stelo as the first over-the-counter CGM system for adults who do not take insulin, widening access beyond traditional prescription-only devices.

Now that clearance has been expanded to children from 2 years of age who do not use insulin, pushing Stelo firmly into the family diabetes toolbox and broadening its addressable user base.

How it feels day to day

In everyday use, Stelo aims to be quiet rather than demanding: customizable alerts instead of constant alarms, trend arrows instead of aggressive color warnings, and a timeline that invites curiosity about patterns rather than fear of individual spikes.

For many type 2 patients used to sporadic lab values, seeing a gentle curve instead of isolated numbers can be both sobering and motivating at the same time.

Pricing and where you get it

Dexcom markets Stelo as an over-the-counter product in the United States, available without a prescription through retail and online channels, with pricing structured per sensor pack rather than a long-term hardware commitment.

There is currently no broad listing for Stelo on German retail platforms; for now, the product story is clearly US-centric and tied to the American regulatory framework and insurance landscape.

Where it sits in Dexcom's lineup

Within Dexcom's portfolio, Stelo lives alongside G7 and future closed-loop integrations, not as a replacement but as a parallel track for earlier-stage and non-insulin-managed diabetes.

For Dexcom, that means a much larger potential audience, but also the challenge of speaking to people who may never have seen themselves as "patients" needing hardware on their skin.

Company context and stock reference

Dexcom has spent years refining prescription CGM for insulin users; Stelo marks a deliberate step into lifestyle-oriented metabolic health while staying under the regulated medical umbrella.

Shares of Dexcom Inc. (US2521311074) trade on Nasdaq in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.